A long‐term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of the European Academy of Dermatology and Venereology

• Publication date

  2007-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1468-3083.2006.01981.xPMID 17309464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vitiligo‐Like Lesions and Diffuse Lightening of the Skin in a Pediatric Patient Treated with Imatinib Mesylate: A Noninvasive Colorimetric Assessment

  2006cited by this paper
• Loss of skin pigment caused by imatinib therapy

  2005cited by this paper
• Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib

  2005cited by this paper
• Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases.

  2005cited by this paper
• Imatinib mesilate (Glivec®): a systemic depigmenting agent for extensive vitiligo?

  2005cited by this paper
• Cancer‐related fatigue: Evolving concepts in evaluation and treatment

  2004cited by this paper
• Imatinib mesylate causes hypopigmentation in the skin

  2004cited by this paper
• Hypopigmentation in an African patient treated with imatinib mesylate: a case report.

  2003cited by this paper
• Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.

  2003cited by this paper
• Molecular mechanisms of transformation by the BCR-ABL oncogene.

  2003cited by this paper
• Screening strategies in c282y‐linked haemochromatosis

  2003cited by this paper
• Imatinib: a targeted clinical drug development.

  2003cited by this paper
• Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.

  2003cited by this paper
• Imatinib mesylate causes hypopigmentation in the skin

  2003cited by this paper
• Imatinib mesylate--a new oral targeted therapy.

  2002cited by this paper
• Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.

  2002cited by this paper
• The impact of epidermal melanin on objective measurements of human skin colour.

  2002cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Analytic quantification of phototype‐related regional skin complexion

  2001cited by this paper
• Skin color measurements: comparison between three instruments: the Chromameter®, the DermaSpectrometer® and the Mexameter®

  2000cited by this paper
• The biology of chronic myeloid leukemia.

  1999cited by this paper
• A long‐term time course of colorimetric evaluation of ultraviolet light‐induced skin reactions

  1999cited by this paper
• The SCF/KIT Pathway Plays a Critical Role in the Control of Normal Human Melanocyte Homeostasis

  1998cited by this paper
• The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis.

  1998cited by this paper
• Site, gender and age variation in normal skin colour on the back and the forearm: tristimulus colorimeter measurements

  1997cited by this paper
• Interlaboratory comparison and validity study of the Minolta ChromaMeters CR‐200 and CR‐300

  1996cited by this paper
• Practical applications of cutaneous colorimetry.

  1995cited by this paper
• Human piebald trait resulting from a dominant negative mutant allele of the c-kit membrane receptor gene.

  1992cited by this paper
• Skin colour typology and suntanning pathways

  1991cited by this paper
• Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism.

  1991cited by this paper

• Vitiligo-like lesions following imatinib mesylate therapy: a case series and review of literature

  2023cites this paper
• Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposition and study of hypopigmentation as treatment's prognostic factor

  2020cites this paper
• KIT as a therapeutic target for non‐oncological diseases

  2019cites this paper
• Examine the skin and thoroughly review medical/medication history when considering a diagnosis of drug-induced pigmentation

  2019cites this paper
• An Update on Drug-Induced Pigmentation

  2018cites this paper
• Blue Man: Melaninophagia Secondary to Imatinib

  2017cites this paper
• Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.

  2016cites this paper
• European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

  2016cites this paper
• Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study

  2014cites this paper
• Anomalies pigmentaires induites par les traitements anticancéreux. Deuxième partie : les thérapies ciblées

  2013cites this paper
• Inhibition of c-Kit signaling by diosmetin isolated from Chrysanthemum morifolium

  2013cites this paper
• EVUE GÉNÉRALE nomalies pigmentaires induites par les traitements nticancéreux . Deuxième partie : les thérapies iblées igmentary disorders induced by anticancer agents . Part II : Targeted therapies

  2013cites this paper
• Piebaldism

  2013cites this paper
• [Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].

  2013cites this paper
• Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate

  2012cites this paper
• Emerging new technology: QSAR analysis and MO Calculation to characterize interactions of protein kinase inhibitors with the human ABC transporter, ABCG2 (BCRP).

  2010cites this paper
• In Vivo Data

  2010cites this paper
• Dermopatie in pazienti in trattamento con Imatinib mesilato

  2010cites this paper
• Review Emerging New Technology : QSAR Analysis and MO Calculation to Characterize Interactions of Protein Kinase Inhibitors with the Human ABC Transporter , ABCG 2 ( BCRP )

  2010cites this paper
• 10 – Disorders of pigmentation

  2010cites this paper
• [New drugs in oncology and skin toxicity].

  2009cites this paper
• Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro

  2009cites this paper
• Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.

  2009cites this paper
• Effets cutanés des nouvelles molécules utilisées en cancérologie

  2009cites this paper
• Mise au point Effets cutanés des nouvelles molécules utilisées en cancérologie New drugs in oncology and skin toxicity

  2009cites this paper
• Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems

  2008cites this paper
• Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems.

  2008cites this paper
• Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors.

  2008cites this paper
• Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib

  2008influential citation
• In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.

  2007cites this paper